Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis. - Privitera G; Bezzio C; Figlioli G; D?Amico F; Mendes J; Varca S; Zingone F; Rodriguez-Lago I; Onali S; Caprioli FA; Chaparro M; Barreiro-de-Acosta M; et al. (Clinical Gastroenterology and Hepatology, 2026)